2,000
Participants
Start Date
April 7, 2017
Primary Completion Date
March 15, 2019
Study Completion Date
March 15, 2019
Fycompa
Oral suspension
Albert Einstein College of Medicine, New York
Columbia University Medical Center, New York
Northwell Health, New York
Icahn School of Medicine at Mount Sinai, Hartsdale
Pennsylvania, Pittsburgh
Albert Einstein Medical Center, Philadelphia
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Duke University Medical Center, Durham
Meridian Clinical Research, Savannah
Nemours Children's Hospital, Orlando
Pediatric Neurology PA, Orlando
Nicklaus Children's Hospital, Miami
Boca Raton Regional Hospital, Boca Raton
University of South Florida, Tampa
Capernaum Medical Center, Lakeland
Doctors hospital of Sarasota, Sarasota
Intercoastal Medical Group, Sarasota
Le Bonheur Children's Hospital - PIN, Memphis
Fort Wayne Neurological Center, Fort Wayne
Wayne State University, Detroit
Henry Ford Health System, Detroit
Spectrum Health System, Detroit
Spectrum Health Medical Group, Grand Rapids
Minnesota Epilepsy Group, Saint Paul
Carle Foundation Hospital, Urbana
University of Texas Health Science Center at Houston, Houston
Austin Epilepsy Center, Austin
Colorado Springs Neurological Associates, Colorado Springs
Consultants in Epilepsy & Neurology PLLC, Boise
Arizona Age Reversal & Neurology Clinic, Phoenix
Bronislava Shafran, MD, PC, Phoenix
Banner - University Medical Center Phoenix, Phoenix
Arizona Neurological Institute, Sun City
The University of Arizona Department of Neurology, Tucson
Valley Children's Hospital, Madera
UC Davis Medical Center, Sacramento
Sutter Health, Sacramento
Oregon Health and Science University, Portland
Auburn Neurological Institute, Auburn
Northwest Neurology & Electrodiagnostic Center, Auburn
Seattle Children's Hospital - PIN, Seattle
Tufts Medical Center, Boston
Northeast Regional Epilepsy Group, Hackensack
MultiCare Institute for Research and Innovation, Tacoma
Eisai Inc.
INDUSTRY